Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
March 2018
-
Media ReleaseNovartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVOBasel, March 28, 2018 - Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting,…
-
Media ReleaseAveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1CHICAGO, March 27, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening…
-
Key ReleaseNovartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic prioritiesPrice reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term…
-
Key ReleaseNovartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrierenPreis stellt für Novartis einen attraktiven Wert dar Verkaufserlös wird in Übereinstimmung mit den Prioritäten für die Kapitalallokation verwendet, einschliesslich für Bolt-on-Akquisitionen Verkauf…
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar infliximabSandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a…
-
Media ReleasePhase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MSEXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate…
-
Media ReleaseNovartis drug Tasigna® approved by FDA to treat children with rare form of leukemiaTasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…
-
Media ReleaseNovartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapiesCollaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development…
-
Media ReleaseAveXis Enters into Licensing Agreement with GenethonIncludes exclusive worldwide rights to AAV9-SMN product and route of administration CHICAGO and ÉVRY, France, March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and Genethon today…
-
Key ReleaseNovartis announces changes to the Executive Committee to support strategic prioritiesBertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger…
-
Key ReleaseNovartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten anBertrand Bodson, Chief Digital Officer, wird in die Geschäftsleitung von Novartis berufen Steffen Lang, Global Head Novartis Technical Operations, wird in die Geschäftsleitung von Novartis berufen…
Pagination
- ‹ Previous page
- 1
- …
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- …
- 100
- › Next page